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Cancer genomeCurrently, human cancer genomics is making great progress, and many mutations of new cancer driver genes
have been detected at an unprecedented rate in a variety of human cancers. Many details of the genetic alter-
ations in cancer cell genomes have been revealed by the massively parallel sequencing. Long-lasting aneu-
ploidy caused large-scale somatic copy number alterations remains a difﬁculty as there are too many genes
located on such big chromosomal fragments, and this cannot simply be solved by increasing sequencing
depth and tumor sample numbers. Comparative oncogenomics may provide us with a solution to this prob-
lem. Here, we review some of the common animal cancer models and propose to analyze cancer cell
genomics in vertebrate phylogenetic backgrounds. Thus phylooncogenomics may provide us with a unique
perspective on he nature of cancer biology unattainable by single species studies.
© 2013 The Authors. Published by Elsevier B.V. This is an open access article under the
(http://creativecommons.org/licenses/by-nc-nd/3.0/).
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Cancer is essentially an aging-related disease, with most of adult
cancers found in the latter half of the lifespan. With the increase of
the expected average lifespan of human beings, cancer will continue
to be one of the major health threats in the future due to its world-
wide prevalence and the lack of effective treatments (Yancik, 2005).
In the past several decades, substantial research endeavors have
been made, because the effectiveness of controlling cancer dependse terms of the Creative Com-
orks License, which permits
in any medium, provided the
arrison Street, West Lafayette,
ax: +1 765 494 9830.
blished by Elsevier B.V. This is an oon our knowledge of the nature of the disease. For example, upon
learning that cancer cells usually divide more rapidly compared to
normal cells, chemotherapy targeting cellular proliferation was created
and it remains the most common treatment regime of cancer after-
wards (Varmus, 2006). With advances in molecular and cellular mech-
anisms of tumorigenesis, targeting therapies using less toxic agents
such as hormones, antibodies, and enzyme inhibitors were invented.
The best example is imatinib, a kinase inhibitor which speciﬁcally in-
hibits the chimera protein, ABL–BCR, in some forms of chronic myeloid
leukemia (O'Brien et al., 2003).More importantly, this speciﬁc targeting
approach provides great hope in conquering this notorious disease.
One of the prerequisites of cancer targeting therapy is knowing
the speciﬁc alterations that are only or mainly present in cancer
cells, thus we can speciﬁcally target cancer cells in effective ways. To-
wards this rationale, many levels of alterations have been explored,
such as histology, biochemistry, metabolism, and genetics (Pierce et al.,pen access article under the CC BY-NC-ND license
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genetic changes in the cancer genome have been discovered at an un-
precedented rate. These changes include: single nucleotide pointmuta-
tions; frame reading shifting mutations caused by both insertions and
deletions; chromosomal rearrangements including translocations, in-
versions, and copy number changes of protein coding and regulatory re-
gions and may occur simultaneously in a single tumor (Stratton et al.,
2009). Additionally, the mutation repertoires can be different among
cancer cells in a single tumor; this is even evident by the different chro-
mosome numbers. It has been estimated that a tumor can generate bil-
lions of mutations (Klein, 2006). Clearly, not all genetic alterations
equally contribute to cancer progression. Mutations that are positively
selected for and are advantageous in growth, tissue invasion andmetas-
tasis are deﬁned as “drivers.”Mutations that are byproducts of genomic
instability, are not selected for, and do not confer cancer development
are named “passengers.” Very recently, a “mut-driver” deﬁnition has
been proposed to precisely describe the genes whose mutations could
cause cancers (Vogelstein et al., 2013).
Identifying cancer drivers is one of the central goals of current cancer
research (Stratton et al., 2009), as not only are they essential for under-
standing the molecular mechanisms of cancer biology, but they may
also serve as potential therapy targets and markers for diagnosis and
prognosis. The current list of known “cancer genes” is about 488, ac-
cording to the Cancer Gene Consensus (Futreal et al., 2004; Santarius
et al., 2010). This list appears far from complete, as many new cancer
driver genes are constantly being discovered with the completion of
more and more cancer genomes. The International Cancer Genome
Consortium (ICGC) network of cancer genome projects was initiated
to target the mutational repertoire in 50 of the most common human
cancer types (Hudson et al., 2010). This was only possible because of
the completion of the Human Genome Project and advances in massive
parallel sequencing technologies. To date, many important discoveries
have been made or conﬁrmed using these high-throughput technolo-
gies. However, even with these new technologies, identifying cancer
driver genes still remains challenging due to the heterogeneities and
mutational hierarchies.
2. Heterogeneity in cancer genome and somatic evolution
Tumor development is thought to occur as a somatic evolutionary
process in which mutations are accumulated in a sequential manner
(Merlo et al., 2006; Nowell, 1976). Like evolution on the whole organ-
ism level, themutation process in cancer is stochastic. Very recently, ev-
idence of Darwinian evolution has been conﬁrmed in human pancreatic
cancer and leukemia using sequencing and microarray (Campbell et al.,
2008, 2010; Notta et al., 2011; Sisman and Geyikoglu, 2008; Yachida
et al., 2010). Selections from the micro- and macro-environments of
the cells determine which mutation(s) are retained and which ones
are eliminated (Gillies et al., 2012; Merlo et al., 2006). The mutations
giving cell growth advantages over surrounding cells are generally
selected, and thus they are likely to be cancer drivers that give rise to
the tumor cells' hallmarks (Hanahan and Weinberg, 2011; Stratton,
2011; Stratton et al., 2009). Conversely,many other bystander genemu-
tations cannot be eliminated rapidly enough and thus they stay in the
cancer genome as passengers. Therefore, multiple levels of genetic het-
erogeneity (intra- and inter-tumoral, inter- and intra-metastatic, and
inter-patient heterogeneities) were frequently revealed by traditional
cytogenetics and recent genomic sequencing analysis (Almendro et al.,
2013; Heppner, 1984; Marusyk et al., 2012). For example, it has long
been recognized from earlier cytogenetic studies that there is almost
no consistent karyotype in different cancer cells within the same solid
tumor (Wolman, 1986). Similarly, the genes and genomes have recently
been noticed in a similar situation. If tumorigenesis really is an evolu-
tionary process, the evolutionary biological approaches, such as phylo-
genetic analysis, should be able to be applied to trace the natural
history of cancer cells. Indeed, recently genomic sequencing and copynumber analysis methods successfully tracked the cancer cell develop-
ment process and the relationships between the original tumor and
subsequent metastatic tumors (Campbell et al., 2008; Gerlinger et al.,
2012; Navin et al., 2010; Tsao et al., 2000). This kind of information on
cancer cell nature history not only is very important for us to under-
stand the dynamic processes of tumor formation, but also might serve
as guidance for therapeutic strategies.
3. Animal models of human cancers
Animal models play a very important role in our understanding of
cancer biology, such as in the identiﬁcation of novel cancer drivers, val-
idating potential oncogenes and tumor suppressor genes, investigation
of molecular mechanisms, and testing new cancer therapy strategies.
Currently, there are several popular cancer models in the cancer re-
search community.
The mouse model has a long history in cancer research as the most
extensively usedmodel systemdue to itsmature geneticmanipulations,
relative short breeding time and the availability of inbred strains. For ex-
ample, inducible and tissue-speciﬁc genemanipulation can be achieved
usingmouse embryonic stem cell and advanced cre-recombinasemedi-
ated knockout and knockin technologies (Cheon and Orsulic, 2011;
Frese and Tuveson, 2007). In addition, N-ethyl-N-Nitrosourea (ENU)
chemical, murine retrovirus-mediated (murine leukemia virus and
mouse mammary tumor virus), and transposon-based mutagenesis
(Sleeping Beauty and PiggyBac) have also been utilized in the mouse
to identify novel cancer driver genes (Ding et al., 2005; Dupuy et al.,
2005; Hrabe de Angelis et al., 2000; Kool and Berns, 2009; Nolan et al.,
2000). Moreover, chromosomal engineering strategies have been
successfully applied to the mouse model in order to mimic bigger
regions of chromosomal deletion and duplication that frequently
occur in human cancer genomes (Yu and Bradley, 2001; Yu et al.,
2006). Since the mouse is a different species, it is not surprising that
many differences between human and mouse tumor biology have
been reported in the literature. For example, the common laboratory
mouse (Mus musculus) possesses more active telomerase, and thus the
tumors in genetically engineered mice generally possess fewer genetic
alterations, including aneuploidy, when compared to corresponding
tumors in humans. In order to make the mouse tumor cells aneuploid,
like those of human tumors,more genes have to bemanipulated inmul-
tiple pathways (Maser et al., 2007; Moens, 2008). Differences in human
andmouse tumor biology are also evidentwith regard to the tumor type
spectrums within the same orthologous cancer gene mutations. For
example, mouse mutations to p53 result in multiple sarcomas and lym-
phomas, while human p53 mutations result predominantly in carcino-
mas and some sarcomas (Jacks et al., 1994). In regard to the number of
essential genetic alterations to convert normal ﬁbroblasts to tumorigenic
cells, aminimumof six alterations is needed for human cells; only two are
sufﬁcient for mouse cell transformation (Rangarajan et al., 2004). Inter-
estingly, this ﬁts the Peto's paradox hypothesis, which suggests that
there are stronger tumor repressormechanisms in larger longer-lived an-
imals than in smaller sized animals with shorter lifespans due to natural
selection (Peto et al., 1975). Recent comparative genomics revealed that
the mouse and human share about 15,213 genes. The mouse has 2785
unique genes that do not have homologous genes in human; conversely,
human has 3189 genes that the mouse does not possess (Howe et al., in
press). Though greater knowledge has been achieved using the mouse
model, clearly human cancers cannot be completely recapitulated using
this model. Thus, caution should be made when general conclusions are
extrapolated from single species data.
The zebraﬁsh is rapidly becoming a popular model organism for
studying cancer and a number of tumor models have been made by
the transgenic expression of oncogenes or via the mutation of tumor
suppressor genes (Liu and Leach, 2011;Mione and Trede, 2010). The ev-
idence that ﬁsh can mimic human cancer comes frommultiple sources.
First, human oncogenes and tumor suppressor genes can induce tumors
50 G. Zhang et al. / Applied & Translational Genomics 2 (2013) 48–54in zebraﬁsh. Human oncogene active mutants (e.g. c-myc, b-raf, k-ras)
have been successfully used for creating zebraﬁsh cancer models
(Dovey et al., 2009; Langenau et al., 2003; Patton et al., 2005). Likewise,
loss of function in the tumor suppressor gene, tp53, resulted in the for-
mation of cancer in the zebraﬁsh although it gave rise to a different
tumor spectrum (Berghmans et al., 2005; Parant et al., 2010). This phe-
nomenon that hereditary mutations in the same orthologous cancer
gene may give rise to different tumors spectrums in different species
is supported in the use of the mouse model. For example, certain MET
gene mutations lead to hereditary renal carcinoma in human, while in
the mouse they give rise to various sarcomas depending on the types
ofmutations (Graveel et al., 2005). Thismay be caused by the varied tis-
sue speciﬁcity of the cancer genes in different animal models. Second,
zebraﬁsh tumors have been shown to have similar gene expression
signatures to human tumors. For example, the chemically induced ﬁsh
liver tumor, and conditional k-ras inducedmelanomas and rhabdomyo-
sarcoma have been reported to share similar transcriptomes with
human corresponding tumors, respectively (Dovey et al., 2009; Lam
et al., 2006; Langenau et al., 2007). Third, the ﬁsh tumors are cytogenet-
ically aneuploidy like humans. Very recently, after strictly examining
zebraﬁsh malignant peripheral nerve sheath tumors (MPNST) that
were induced by ribosomal protein (rp) and tp53mutations, we revealed
that these tumors are highly aneuploid, and that the aneuploid chromo-
somes show preferential presentations within a tumor and among
ﬁsh tumors. For example, within a single ﬁsh tumor there is often pref-
erential overrepresentation of chromosome 25 with simultaneous un-
derrepresentation of chromosome 15 (Zhang et al., 2010). This ﬁnding
is very similar with the aneuploidy chromosomes in human solid
tumors (Wolman, 1986). Moreover, there are also recurrent focal copy
number alterations (CNA) as well as human solid tumors. We
succeeded in ﬁnding cancer driver genes within recurrent focal CNAs
using array-comparative genomic hybridization (CGH) and Illumina
deep sequencing technology (Zhang et al., 2010). Similar to the mouse
cancer model, genetic manipulation such as forward genetic screening
with ENU, retroviruses, and targeted mutagenesis have also been suc-
cessful in zebraﬁsh (Amsterdam et al., 1999; Mullins et al., 1994). It is
not surprising that many developmental processes and disease mecha-
nismswere found to be similar to humans. Zebraﬁsh share 12,897 strict
homologous genes with humans. This gene number is just slightly less
compared with the orthologous genes between mouse and human
(Howe et al., in press). Thus, it is reasonable to expect that certain prop-
erties of human cancer biology can be recapitulated using zebraﬁsh can-
cer models.
While the mouse and zebraﬁsh compose the two major cancer
model organisms, there exist other vertebrate cancer models. Among
them, the dog is the most prominent one. Compared to tumors of
mouse and zebraﬁsh, most dog tumors are spontaneous, like the ones
in the human population (Rowell et al., 2011). Similar to humans, the
cancer rate in dogs has increased in recent years due, in part, to longer
life expectancy resulting from better nutrition and veterinary care.
Many human cancer gene mutations, like TP53 and KIT, have subse-
quently been identiﬁed in canine cancers (Paoloni and Khanna, 2008).
Genetic variations within each dog breed have been greatly reduced
compared to humans and this makes them an ideal model system for
genetic association studies of disease mapping and pharmacogenomics.
One disadvantage of the caninemodels is the few genetic manipulation
approaches available to test causal effects of candidate genes. Human,
mouse, and dog genomes share about 13,816 genes with a 1:1:1
orthology (Lindblad-Toh et al., 2005). Thus, similar to the mouse and
zebraﬁsh, human cancer biology cannot be completely recapitulated
in the dog.
Again, there is no single species disease model that completely
mimics human disease pathogenesis, as every species has a unique eco-
logical and evolutionary niche. Employingmodels frommultiple species
and proper comparative analysis are essential for understanding the
mechanisms of human diseases including cancer.4. Comparative oncogenomics
Currently, themethod predominately used forﬁnding cancer drivers
is limited to ﬁnding statistical signiﬁcance among certain number of
tumors, usually within a single species. The approach is greatly affected
by the very small signal-to-noise ratio as well as the choice of sampling
siteswithin a given tumor. As such, thismethod requires relatively large
sample sizes (e.g. 250 samples per tumor in human cancer genome
projects) (Hudson et al., 2010) and it is very inefﬁcient when dealing
with large-scale genetic alterations. This is especially true for large
and whole chromosomal copy number changes, which are mainly
caused by aneuploid chromosomes in cancer cells. Aneuploidy is one
of the most common genetic changes in human tumors, especially
solid tumors (Mitelman et al., 2013). The discovery of the chromosome
changes can be traced back to a century ago. Theodor Boveri and David
von Hanseman proposed the ﬁrst hypothetical cancer origin based on
chromosome number changes (Hardy and Zacharias, 2005). However,
the biologicalmeaning of this aneuploidy remains unclear.Whether an-
euploidy is causative or simply a byproduct of genomic instability has
been actively debated as the etiology of human cancers (Duesberg,
2005). Accumulating evidence shows that these chromosomal abnor-
malities are indeed not random and suggests that they play certain
roles during tumorigenesis. In terms of cytogenetics, aneuploidy is
synonymous with whole chromosome or arm-level copy number
changes that are used for modern genomic level studies, usually with
array comparative genomic hybridization (aCGH). Recent large-scale
investigations showed that there were indeed common chromosome
changes in human solid tumors and some alteration patterns are even
shared by many solid tumors (Baudis, 2007; Beroukhim et al., 2010).
In most of the published CNA analysis using a single animal model spe-
cies, only the small-sized focal CNAs (or minimum common regions)
are informative, as they contain manageable numbers of genes for can-
didate gene functional validations. In contrast, identiﬁcation of cancer
drivers on the large-sized CNAs, usually chromosome or chromosomal
arm lengths, remains a challenge. These regions often contain hundreds
to thousands of genes, each requiring functional studies—well beyond
the ability of most average-size laboratories. It has been proposed that
high-throughput screening using RNAi and ORF libraries could be com-
bined for this purpose in order to narrow down the scope (Boehm et al.,
2007; Hahn et al., 2009). Others have shown that integrating the gene
expression data with CNAs could lead to this same purpose (Akavia
et al., 2010). Here, we only focus on an alternative approach, compara-
tive genomics and genetics, for identiﬁcation and biological validation
of cancer driving genetic events, using copy number alterations as an
example.
Animal models, especially the mouse cancer model, have been
extensively used for many years to study many aspects of human can-
cers, from the discovery of tumor initiation genes' to testing cancer
therapeutics (Frese and Tuveson, 2007). Recently, it has been shown
that some mouse tumors also contain many CNAs, including both
those at the whole chromosome level and more focal changes (Kim et
al., 2006; Zender et al., 2006). Like humans, recurrent focal changes in
themouse genome are useful in identifying cancer drivers. More impor-
tantly, the mouse models have helped pinpoint cancer driver genes by
comparing the gene contents of recurrent CNAs in both human and
mouse tumors. Likewise, it has been shown effective with the focal
CNAs in mouse liver tumors, melanoma, and osteosarcoma (Kim et al.,
2006; Maser et al., 2007; Molyneux et al., 2010; Zender et al., 2006).
However, this approach reaches potential limitations when applied to
larger regions, especially at whole chromosome levels. This is because
the gene locations in humans and mice are so highly conserved that
the majority of the gene linkages are nearly identical. Thus it is still
not efﬁcient in eliminating the passenger genes. Other currently avail-
able mammal cancer models, such as the dog, are similar to the
mouse for comparative purposes due to their close evolutionary
distance.
Fig. 1. Gene positions were reshufﬂed in human, zebraﬁsh and mouse genomes. (A) Circos scatter plot for the chromosomal locations of orthologous genes between mouse (Mmu)
and human (Hsa). (B) The syntenic relationship between zebraﬁsh (Dre) and human (Hsa). The plot was generated using the published synteny database (Catchen et al., 2009). The
orthologous gene counts in the shared chromosome fragments are connected with lines.
51G. Zhang et al. / Applied & Translational Genomics 2 (2013) 48–54Due to these common features among ﬁsh, human and mouse tu-
mors and the conservation of genes' functions, it is reasonable to assume
that most driver genes within the preferential whole-chromosome and
focal-CNAs are also shared among vertebrates. As these and other data
show that, some preferences are speciﬁc to one type of tumor while
some preferences are shared by many different tumor types. Because
the orthologous gene locations along the chromosomes were reshufﬂed
during evolution in different vertebrates, phylogenetically close species
share large blocks of conserved syntenies (Kasahara et al., 2007;
Kirkness et al., 2003). For example, the mouse and human genomes
share large regions of conserved chromosome fragments containing
similar gene contents (Fig. 1A). This is also the rationale for using the
mouse to model human aneuploid syndromes (e.g., Down syndrome)
(Reeves et al., 1995). On the other hand, zebraﬁsh and humans shareFig. 2. Dot plot (generated from the synteny database, Catchen et al., 2009) shows the geneconserved regions to a much lesser degree; instead, most of the con-
served syntenies contain much smaller fragments (Fig. 1B). It is appar-
ent from numerous phylogenetic studies that ﬁsh genes were widely
dispersed among the 23 pairs of human chromosomes during evolution
(Kasahara et al., 2007; Schartl et al., 2013; Woods et al., 2000). Con-
versely, genes that lie on a particular human chromosome are often
found together on a single mouse chromosome. The small syntenies
between the zebraﬁsh and human genome make the zebraﬁsh cancer
models uniquely useful in identifying cancer drivers on large CNAs by
comparative oncogenomics. This is because the overlapping of genes
between ﬁsh and human preferential whole-chromosome and focal-
CNAs is much less.
In humanmalignant peripheral nerve sheath tumors andmany other
human cancers, the most frequently over-represented chromosome is 7,position relationships between human chromosome 7 and all zebraﬁsh chromosomes.
Fig. 3. Phylooncogenomic approach for cancer driver identiﬁcation, and understanding the nature of cancer biology.
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zebraﬁsh MPNSTs, the most frequently over-represented chromosome
is 25, followed by 11, 10, 23 and 22 (Zhang et al., 2010). Human chromo-
some 7 alone possesses ~1750 genes. In contrast, there are only 68 on
ﬁsh chromosome 25, 18 on chromosome 11, and 34 on chromosome
10 (Fig. 2). As the presence of unbalanced chromosomes is the result of
tumor evolution selection, these common genes could be candidates
that underlie the growth advantage conferred by extra copies of
human chromosome 7. The same logic can be applied to genes that lie
on chromosomes that are under-represented in both ﬁsh and human tu-
mors and generating a list of genes whose under-representation favors
tumor growth. In humans, theMET oncogene lies on chromosome7. Am-
pliﬁcation of chromosome 7 carrying a mutated form of MET underlies
an inherited cancer in humans (Lee et al., 2000; Schmidt et al., 1997).
It is thought that the presence of wild-type MET may explain, at least
in part, the frequent over-representation of chromosome 7 in many
human cancers (Grabellus et al., 2010; Jenkins et al., 1998; Zhuang
et al., 1998). Strikingly, the zebraﬁsh met gene lies on ﬁsh chromosome
25. One of other genes also presented in the overrepresented zebraﬁsh
chromosome 25 is fgf6a. We have shown that fgf over-expression accel-
erates the onset ofMPNSTs in combinationwith a p53mutation, demon-
strating that fgf is probably a driver in ﬁsh MPNSTs (Zhang et al., 2010).
This result indicates that there are at least two drivers on chromosomes
that are over-represented in ﬁsh tumors and it is possible that there are
more. This discovery is consistent with the report ofmultiple tumor sup-
pressors in chromosomal region 8p22 (Solimini et al., 2012; Xue et al.,
2012). Combined with genetic functional validations, the zebraﬁsh
model provides us a unique model to catalogue human cancer drivers
on the recalcitrant large scale CNAs.
5. Phylooncogenomics, beyond the CNAs
Although mouse–human and zebraﬁsh–human cancer genomic
comparisons are helpful to pinpoint the cancer driver genes on large
CNAs in corresponding human tumors, this comparative approachshould not be limited to two species only. Comparison of cancer geno-
mics from multiple vertebrate species will be more powerful to narrow
down the scope of cancer driver genes on the large scales CNAs. The
early vertebrates, chondrichthyes, may be particularly interesting, as
their genomes were not duplicated as teleosts (Venkatesh et al., 2007).
The increased phylogenetic distance of these cartilaginous ﬁshes to
human could be useful to breakdown the chromosomally linked drivers
and passengers. However, at the current time, the zebraﬁsh is particular-
ly useful as it is a model organism whose genomic and other biological
infrastructures are much more mature compared to other non-model
organisms. With advances in current sequencing technologies, we
expect that other ﬁsh tumor models will play their roles in the future.
For example, platyﬁsh and lamprey genomes have recently been
published (Schartl et al., 2013; Smith et al., 2013). Ultimately, multiple
species tumor comparison could further reduce the passenger genes in
a given tumor, thuswe coined theword “phylooncogenomics” to accom-
modate this approach (Fig. 3). Common evolutionarily conserved cancer
drivers and species-speciﬁc drivers canbe identiﬁed and functionally test-
ed in this way. For example, cancer genomes of MPNSTs from human
(Beert et al., 2011; Brekke et al., 2010), mouse (Cichowski et al., 1999;
Vogel et al., 1999), Tasmanian devil (Murchison et al., 2010, 2012) and
zebraﬁsh (Zhang et al., 2010) DNA could be compared in the future to
identify common shared cancer drivers and biological tumorigenicmech-
anisms. Another potential candidate for tumor phylooncogenomic studies
could be melanomas from human (Gast et al., 2010; Stark and Hayward,
2007),mouse (O'Hagan et al., 2003), zebraﬁsh (Patton et al., 2005),meda-
ka (Schartl et al., 2010) and platyﬁsh (Xiphophorus) (Meierjohann and
Schartl, 2006). The platyﬁsh itself is a long used melanomamodel as cer-
tain hybrid species naturally develop a variety of degrees of melanoma
(Meierjohann and Schartl, 2006).
Though we use CNAs as the basis for phylooncogenomic analysis,
this approach should not be only limited to CNAs. Other genetic abnor-
malities, including point/frameshift mutations, indels, chromosome
translocations, even gene expression and methylation and other epige-
netic patterns that present in the tumors could also be investigated in a
53G. Zhang et al. / Applied & Translational Genomics 2 (2013) 48–54similar way. With phylooncogenomics, cancer genomes may be exam-
ined and compared in vertebrate phylogenetic background for common
and distinct features. This is particularly important, as it will not only
deepen our understanding of cancer biology, but will also give us hints
to the discovery of novel cancer drugs. We have seen, on the cellular
level, that a phylogenetic approach has been applied to intra-tumor
heterogeneity and mutational hierarchies.
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